AZD9496 First Time in Patients Ascending Dose Study

NCT02248090 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

ER+ HER2- Advanced Breast Cancer

Interventions

DRUG: AZD9496
DRUG: AZD9496

Sponsor

AstraZeneca